Navigation Links
PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
Date:6/24/2009

PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822.

Oxford, UK (PRWEB) June 24, 2009 -- PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822 .

Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures are delighted to have supported Helsinn in the strategic divestment of its pharmaceutical API manufacturing business. This success was achieved despite the current difficult economic environment and demonstrates why we are recognised as leaders in deal making. It also helps ensure an ongoing future for the Helsinn Chemicals Ireland business and its employees under the new ownership of the Medinco C.F.M. Group."

Please contact:

Dr Fintan Walton, CEO
PharmaVentures Ltd
+44 (0) 1865 784 187

About PharmaVentures Ltd
PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored advisory and transaction services to the Life Scienc
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2

Related biology technology :

1. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
2. Online Career Site Assists Academia in Its Reach
3. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
4. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
5. Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
6. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
7. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
8. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
9. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
10. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
11. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
(Date:5/23/2013)...  Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., ... banking and therapeutics, announced today that StemCyte has become ... Indy car driven by James Jakes ... IndyCar 2013 season.   StemCyte, Inc. and Rahal ... of umbilical cord blood banking and its educational initiative ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 The New ... STEM industries, Black Data Processing Associates (BDPA), is hosting ... June 8, 2013. This all-day event will encourage students ... learn the ins and outs from many of the ... p.m. at the New Jersey Institute of Technology, the ...
(Date:5/23/2013)... SynCardia Systems, Inc. ( http://www.syncardia.com ), ... Canada and CE (Europe) approved Total Artificial Heart, announced ... boasts more than 380,000 visitors annually, is featuring the ... the Freedom® portable driver as part of its $3 ... of its kind. , “BodyWorks combines the latest ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... UPPSALA, Sweden, June 29 , ... Will Fund Gyros to Profitability , ... development, announces that it has raised SEK 80 million,(approximately euro ... Company,s leading shareholder. The new funds will enable Gyros to ...
... Kornberg Associates | Architects ( www.kornberg.com ) has ... new Cognitive & Neurobiological Imaging Center. Ken Kornberg, president ... with Stanford University since 1980 and has completed ... is the two-story, 32,000 square-foot office building for the Stanford ...
... ... elimination, exterior plastic trim and headlight restoration products to the Automotive, RV and Marine ... myriad of industries, to introduce these innovative and eco-friendly products to the pan-national marketplace. ... ...
Cached Biology Technology:Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 4Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 2MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 3
(Date:5/24/2013)... largest and fastest growing open-access publishers, today announces the ... . , A broad scope journal covering all specialties, ... and interactive web platform for the research community to ... Frontiers, real-time and interactive peer-review enables fast, fair and ... an average of three months from submission to final ...
(Date:5/24/2013)... to combat metastatic cancer , Cancer cells spread ... immune system. Stimulation of the immune system can help ... that cause the immune system to ignore cancer cells. ... suppress the immune system response. In this issue of ... by Ronald Levy at Stanford University found that regulatory ...
(Date:5/24/2013)... spread and grow by avoiding detection and destruction by ... help to eliminate cancer cells; however, there are many ... cells. Regulatory T cells are immune cells that function ... of the Journal of Clinical Investigation , researchers ... regulatory T cells that infiltrate tumors express proteins that ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8
... reproductive apparatus of a model virus is bolstering the idea ... important human diseases such as AIDS, SARS and hepatitis C ... vulnerable to broad-spectrum antiviral agents. In a study published ... of Science Biology, a team of researchers from the Howard ...
... 2007 It,s not a good idea to put all your ... in the parched Sonoran desert of southern Arizona and northern Mexico, ... senita cactus -- both for its food and for a place ... moth, the only species that pollinates its flowers. Senita cacti and ...
... In some ways, certain tumors resemble bee colonies, says pathologist ... specific role, and just a fraction of the cells serve ... an unspecialized state and seed new tumors. These cells can ... bulk of the tumor. These queens are cancer ...
Cached Biology News:Features of replication suggest viruses have common themes, vulnerabilities 2Features of replication suggest viruses have common themes, vulnerabilities 3Which came first, the moth or the cactus? 2Which came first, the moth or the cactus? 3Newly created cancer stem cells could aid breast cancer research 2Newly created cancer stem cells could aid breast cancer research 3
... Osteoclast cells form from a hematopoietic stem ... attaching to the bone surface and lowering ... of around 4.5. The bone mineral is ... differentiation and function is controlled primarily by ...
... Receptor-gamma (PPAR) is a member of ... transcription factors that heterodimerize with retinoic ... in the regulation of glucose and ... class of anti-diabetic agents called thiazolidinediones ...
... Nucleic acid hybridization Preparation ... mg BSA, 50 mg ficoll ... with 5 ml of water ... for molecular biology Density: 1.00 ...
... ProteinChip Antibody Capture Kit ... and optimization steps typically ... interactions. This kit enables ... of multiple antigens based ...
Biology Products: